Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 and Influenza Vaccine Co-administration in Immunocompromised Hosts
NCT06599658Phase 2Recruiting
- Sponsor
- McGill University Health Centre
- Start
- Nov 2024
- Primary completion
- Jan 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elasomeran and Fluzone Trivalent in coronavirus disease 2019 (COVID-19) and influenza (4 arms), sponsored by McGill University Health Centre. Primary endpoint: Median neutralization capacity against prevalent SARS-CoV-2 variant at 12 months. Started Nov 2024; status: recruiting.
02
Drugs
elasomeranFluzone Trivalent
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06599658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599658.